ALHC Director Sells 25k Shares for $400k Under 10b5-1 Plan

Q: How many Alignment Healthcare shares did Director Joseph Konowiecki sell?

He sold 25,000 common shares on 31 Jul 2025.

Q: At what price were the ALHC shares sold?

The shares were sold at $16.00 each.

Q: What is Konowiecki's remaining ALHC ownership after the sale?

He now directly owns 1,152,049 shares .

Q: Was the transaction executed under a Rule 10b5-1 plan?

Yes. The plan was adopted on 5 Mar 2025 .

Q: Is Joseph Konowiecki still a director of Alignment Healthcare?

Yes, the filing lists him as a Director with no change in status.

[Form 4] Alignment Healthcare, Inc. Insider Trading Activity

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Form 4 filing for Alignment Healthcare (ALHC) shows Director Joseph S. Konowiecki sold 25,000 common shares on 31 Jul 2025 at $16.00 per share under a pre-arranged Rule 10b5-1 trading plan adopted 5 Mar 2025. Gross proceeds equal roughly $400k.

Following the sale, Konowiecki鈥檚 direct ownership stands at 1,152,049 shares. No derivative securities were reported. The transaction does not alter board status and no other insider activity is disclosed in this filing.

Positive

None.

Negative

Insider sale: Director sold 25,000 shares (~$400k), a potential negative sentiment signal despite being only ~2% of his stake and executed under a 10b5-1 plan.

Insights

TL;DR: Director's $400k sale is modest vs. 1.15 M share stake; neutral-to-slightly negative sentiment signal.

The 25k-share disposal represents only about 2.1% of Konowiecki鈥檚 holdings, so ownership remains substantial. Because the trade was executed under a 10b5-1 plan, it likely reflects pre-scheduled diversification rather than a view on fundamentals. Still, any insider sale can weigh on sentiment, especially given ALHC鈥檚 limited trading float. With no offsetting insider purchases, the filing skews slightly negative but is not materially impactful to cash flows or governance.

08/01/2025 - 06:17 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KONOWIECKI JOSEPH S

(Last)

(First)

(Middle)

1100 W. TOWN & COUNTRY RD.

SUITE 1600

(Street)

ORANGE

92868

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Alignment Healthcare, Inc. [ ALHC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/31/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	07/31/2025		S⁽¹⁾		25,000	D	$16	1,152,049	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Date of Rule 10b5-1 plan adoption: 03/05/2025

Remarks:

	/s/ Christopher J. Joyce, as Attorney-in-Fact, for Joseph S. Konowiecki	08/01/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

How many Alignment Healthcare shares did Director Joseph Konowiecki sell?

He sold 25,000 common shares on 31 Jul 2025.

At what price were the ALHC shares sold?

The shares were sold at $16.00 each.

What is Konowiecki's remaining ALHC ownership after the sale?

He now directly owns 1,152,049 shares.

Was the transaction executed under a Rule 10b5-1 plan?

Yes. The plan was adopted on 5 Mar 2025.

Does the filing report any derivative securities activity?

No derivative securities were acquired or disposed of in this filing.

Is Joseph Konowiecki still a director of Alignment Healthcare?

Yes, the filing lists him as a Director with no change in status.

AG真人官方

[Form 4] Alignment Healthcare, Inc. Insider Trading Activity

Insights

FAQ

How many Alignment Healthcare shares did Director Joseph Konowiecki sell?

At what price were the ALHC shares sold?

What is Konowiecki's remaining ALHC ownership after the sale?

Was the transaction executed under a Rule 10b5-1 plan?

Does the filing report any derivative securities activity?

Is Joseph Konowiecki still a director of Alignment Healthcare?

NASDAQ:ALHC

ALHC Rankings

ALHC Latest News

ALHC Latest SEC Filings

ALHC Stock Data

AG真人官方

Trending News

[Form 4] Alignment Healthcare, Inc. Insider Trading Activity

Insights

Securities Analyst neutral

FAQ

How many Alignment Healthcare shares did Director Joseph Konowiecki sell?

At what price were the ALHC shares sold?

What is Konowiecki's remaining ALHC ownership after the sale?

Was the transaction executed under a Rule 10b5-1 plan?

Does the filing report any derivative securities activity?

Is Joseph Konowiecki still a director of Alignment Healthcare?

NASDAQ:ALHC

ALHC Rankings

ALHC Latest News

ALHC Latest SEC Filings

ALHC Stock Data